iX Biopharma remains a 'buy' from PhillipCapital despite $2.8 million net loss in 1H21

Retrieved on: 2021-02-22 11:26:15

Tags for this article:

Click the tags to see associated articles and topics

iX Biopharma remains a 'buy' from PhillipCapital despite $2.8 million net loss in 1H21. View article details on hiswai:

Excerpt

Overall iX Biopharma's gross margin was down 16% in 1HFY21, improving from the 57% plungea year ago. Operating margins were affected by a ...

Article found on: www.theedgesingapore.com